You are here: Home ยป Archives for NASDAQ

Synchronoss Apresenta Plataforma de Nuvem Pessoal Expandida, Momento da Capsyl e Nova Oferta na CES 2026

BRIDGEWATER, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), líder global e inovadora em soluções de nuvem pessoal, anunciou hoje a expansão dos recursos da sua plataforma de Nuvem Pessoal de marca branca da Synchronoss na CES 2026 em Las Vegas. A empresa também destacou o impulso contínuo da Capsyl, sua solução de nuvem pessoal pronta para uso, e apresentou uma nova experiência digital baseada em eventos focada em momentos compartilhados e envolvimento do grupo.

Recursos Expandidos da Plataforma de Nuvem Pessoal Synchronoss

A Synchronoss está apresentando na CES novas melhorias da sua plataforma de Nuvem Pessoal de marca branca, projetada para ajudar as operadoras e marcas a fornecer serviços de nuvem seguros, escaláveis e diferenciados. As atualizações fortalecem o gerenciamento de conteúdo principal, backup e sincronização entre dispositivos e a inteligência em nuvem, ao mesmo tempo em que introduzem controles aprimorados de privacidade e segurança, como pastas bloqueadas para conteúdo confidencial, permissões de acesso e compartilhamento granulares, e recursos integrados de digitalização de documentos para armazenamento de documentos físicos com segurança.

Momento e Expansão do Mercado da Capsyl

A Synchronoss também está destacando o progresso contínuo da Capsyl, sua solução de nuvem pessoal hospedada e totalmente gerenciada, projetada para implantação rápida por provedores de serviços e marcas de consumo. A Capsyl oferece recursos de nuvem pessoal premium prontos para uso, incluindo acesso entre dispositivos, memórias selecionadas e ferramentas de conteúdo alimentadas por IA, com complexidade operacional mínima.

No aniversário de 1 ano do sucesso do seu lançamento no mercado, a Capsyl está se expande além de sua pegada móvel inicial para dar suporte a tipos de acesso adicionais e casos de uso de proteção ao consumidor, incluindo banda larga fixa e recursos de segurança integrados. Essa expansão viabiliza experiências domésticas mais amplas e de vários dispositivos, e atende à crescente demanda por serviços em nuvem prontos para uso que unem recursos premium, localização e rápido tempo de colocação no mercado.

Prévia de Novo Aplicativo de Eventos e Experiências em Grupo

Além das atualizações da plataforma e do impulso comercial, a Synchronoss está oferecendo uma prévia de um novo conceito baseado em nuvem projetado para eventos e experiências em grupo. Baseado na plataforma de nuvem Synchronoss, o conceito apresenta espaços de nuvem específicos para eventos que reúnem fotos, vídeos e conteúdo relacionado em um só lugar, facilitando a contribuição, o acesso e a revisão de conteúdo vinculado a viagens, celebrações, eventos ao vivo ou atividades em grupo.

A experiência está sendo explorada para uso direto do consumidor, bem como futura distribuição ou integração por meio de parceiros estratégicos. A prévia ilustra como a nuvem pessoal pode evoluir além do armazenamento estático para oferecer melhor suporte à forma como as pessoas capturam, organizam e lembram de experiências juntas, mantendo fortes controles de segurança e privacidade.

“Na CES este ano estamos demonstrando como a Synchronoss continua a fortalecer a base da nossa plataforma de nuvem, ao mesmo tempo em que expande a forma como ela pode ser usada e experimentada”, disse Jeff Miller, Presidente e CEO da Synchronoss Technologies. “Da segurança e inteligência aprimoradas em toda a nossa plataforma, ao crescente impulso da nossa solução Capsyl, à visualização de novas maneiras pelas quais a nuvem pode oferecer suporte a experiências compartilhadas, estamos focados em ajudar nossos parceiros a oferecer serviços confiáveis e significativos aos seus clientes.”

Sobre a Synchronoss 

A Synchronoss Technologies (Nasdaq: SNCR), líder global em soluções pessoais de nuvem, capacita os provedores de serviços a estabelecer conexões seguras e significativas com seus assinantes. Nossa plataforma SaaS Cloud simplifica os processos de integração e promove o envolvimento dos assinantes por meio do uso da inteligência artificial (IA), aprendizado de máquina e outros recursos avançados, resultando em fluxos de receita aprimorados, despesas reduzidas e tempo de comercialização mais rápido. Milhões de assinantes confiam na Synchronoss para proteger suas memórias mais queridas e conteúdo digital importante. Explore como as nossas soluções focadas na nuvem redefinem a forma da conexão digital com seu mundo digital em www.synchronoss.com.

Contato de Relações com a Mídia: 
Domenick Cilea 
Springboard 
[email protected] 

Contato de Relações com Investidores: 
Ryan Gardella 
ICR INC. 
[email protected] 


GLOBENEWSWIRE (Distribution ID 9621299)

Synchronoss Showcases Expanded Personal Cloud Platform, Capsyl Momentum, and Previews New Offering at CES 2026

BRIDGEWATER, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud solutions, today announced expanded capabilities across its white–label Synchronoss Personal Cloud platform at CES 2026 in Las Vegas. The company is also highlighting continued momentum for Capsyl, its turnkey personal cloud solution, and previewing a new event–based digital experience focused on shared moments and group engagement.

Expanded Synchronoss Personal Cloud Platform Capabilities

At CES, Synchronoss is showcasing new enhancements to its white–label Personal Cloud platform designed to help operators and brands deliver secure, scalable, and differentiated cloud services. Updates strengthen core content management, cross–device backup and sync, and cloud intelligence, while introducing enhanced privacy and security controls such as locked folders for sensitive content, granular access and sharing permissions, and integrated document scanning capabilities for securely storing physical documents.

Capsyl Momentum and Market Expansion

Synchronoss is also highlighting continued progress for Capsyl, its hosted and fully managed personal cloud solution designed for rapid deployment by service providers and consumer brands. Capsyl delivers premium personal cloud capabilities out of the box, including cross–device access, curated memories, and AI–powered content tools, with minimal operational complexity.

On the 1–year anniversary following a successful market launch, Capsyl is expanding beyond its initial mobile footprint to support additional access types and consumer protection use cases, including fixed broadband and integrated security capabilities. This expansion enables broader household and multi–device experiences and reflects growing demand for turnkey cloud services that combine premium features, localization, and fast time to market.

Previewing a New Event–Based Group Experience App

In addition to platform updates and commercial momentum, Synchronoss is offering an early preview of a new cloud–powered concept designed around events and group experiences. Built on the Synchronoss cloud platform, the concept introduces event–specific cloud spaces that bring photos, videos, and related content together in one place, making it easy for people to contribute, access, and revisit content tied to trips, celebrations, live events, or group activities.

The experience is being explored for direct–to–consumer use, as well as future distribution or integration through strategic partners. The preview illustrates how personal cloud can evolve beyond static storage to better support how people capture, organize, and remember experiences together, while maintaining strong security and privacy controls.

“This year at CES, we are demonstrating how Synchronoss continues to strengthen the foundation of our cloud platform while expanding how it can be used and experienced,” said Jeff Miller, President and CEO of Synchronoss Technologies. “From enhanced security and intelligence across our platform, to growing momentum for our Capsyl solution, to previewing new ways cloud can support shared experiences, we are focused on helping our partners deliver trusted, meaningful services to their customers.”

About Synchronoss 

Synchronoss Technologies (Nasdaq: SNCR), a global leader in personal cloud solutions, empowers service providers to establish secure and meaningful connections with their subscribers. Our SaaS cloud platform simplifies onboarding processes and fosters subscriber engagement using artificial intelligence (AI), machine learning, and other advanced features, resulting in enhanced revenue streams, reduced expenses, and faster time–to–market. Millions of subscribers trust Synchronoss to safeguard their most cherished memories and important digital content. Explore how our cloud–focused solutions redefine the way you connect with your digital world at www.synchronoss.com.

Media Relations Contact: 
Domenick Cilea 
Springboard 
[email protected] 

Investor Relations Contact: 
Ryan Gardella 
ICR INC. 
[email protected] 


GLOBENEWSWIRE (Distribution ID 9620361)

Nyxoah Fera une Présentation lors de la 44ème Conférence Annuelle J.P. Morgan Healthcare

Nyxoah Fera une Présentation lors de la 44ème Conférence Annuelle J.P. Morgan Healthcare

Mont–Saint–Guibert, Belgique – 29 décembre 2025, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui que le management présentera lors de la 44e conférence annuelle J.P. Morgan Healthcare à San Francisco, le jeudi 15 janvier 2026. La présentation de la Société débutera à 12h00 PT.

Une retransmission audio en direct de la présentation sera disponible en ligne sur la page Relations investisseurs du site Web de la société à l'adresse investors.nyxoah.com.

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001156886)

Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mont–Saint–Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.

A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Contact:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001156886)

Datavault AI Inc. Announces Proposed Dividend of Warrants

  • Record date for the proposed dividend of warrants will be on Jan. 7, 2026
  • The warrants are expected to have a striking price of $5.00 per share of Datavault AI common stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar types of transactions)
  • Each eligible participant is expected to be entitled to receive one (1) warrant to purchase one (1) share of Datavault AI common stock for every sixty (60) shares of Datavault AI common stock owned by such participant and is required to open a wallet with Datavault.

PHILADELPHIA, Dec. 29, 2025 (GLOBE NEWSWIRE) — Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today announced that the Company intends to declare a special dividend distribution of warrants to holders of Datavault AI common stock and holders of certain other Datavault AI equity securities. The expected terms of the warrants are described below. The record date for such proposed dividend is set on Jan. 7, 2026, and the related distribution date has not yet been determined. The Company anticipates that it will announce such information on or before Jan. 7, 2026.

Datavault AI currently anticipates that the terms of the dividend and the warrants to be distributed in connection therewith will include:

  • Eligible Participants: All record and beneficial holders of Datavault AI common stock and holders of certain other equity securities of Datavault AI (with contractual rights to participate in the dividend) as of the record date are expected to be eligible to participate in the dividend, at no cost.
  • Dividend Ratio: Each eligible participant is expected to be entitled to receive one (1) warrant to purchase one (1) share of Datavault AI common stock for every sixty (60) shares of Datavault AI common stock owned by such participant (or deemed to be owned by such participant in the case of other equity securities of Datavault AI for purposes of determining such holder’s right to participate in any such dividend), in each case as of the record date, rounded up to the nearest whole number of warrants. No fractional warrants will be distributed.
  • Exercise Price: The warrants are expected to have a striking price of $5.00 per share of Datavault AI common stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar types of transactions). Datavault AI currently anticipates that the warrants will be exercisable only for cash consideration.
  • Term: The warrants are expected to be exercisable at any time (subject to certain conditions) following the distribution date until they expire on the one (1) year anniversary of the distribution date.
  • Exercise Conditions: The warrants are expected to be exercisable only by holders holding at least one Dream Bowl Meme Coin II token in a digital wallet with the Company as of the applicable exercise time of such warrants (which ownership will be subject to verification by the Company). This condition and any other conditions to the exercise of the warrants are expected to be set forth in a warrant agreement that the Datavault AI expects to file with the Securities and Exchange Commission (the “SEC”) on or prior to the distribution date.

The Company announced the record date to be on Jan. 7, 2026, and the related distribution date for the dividend has not been determined by the board of directors of Datavault AI (the “Datavault Board”) and that the warrants will be governed by a warrant agreement that the Company expects to file with the SEC on or prior to the distribution date.

It is also anticipated that, once determined by the Datavault Board, the record date for the dividend may be changed by the Datavault Board for any reason at any time prior to the distribution date, and distribution of the warrants will be conditioned upon the Datavault Board not having revoked the dividend prior to the distribution date, including for a material change to the solvency or surplus analysis presented to the Datavault Board.

The final terms and conditions of the foregoing dividend and warrants to be distributed in the dividend will be subsequently announced by the Company after the Datavault Board formally declares the proposed dividend and sets the record date and distribution date.

No Offer or Solicitation

This Press Release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

The distribution of the warrants in connection with the proposed dividend has not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), as the distribution of a warrant for no consideration does not constitute a sale of a security under Section 2(a)(3) of the Securities Act. A Form 8–A registration statement and prospectus supplement describing the terms of the warrants will be filed on or before the distribution date with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Holders should read the prospectus supplement carefully, when available, including the Risk Factors section included and incorporated by reference therein.

About Datavault AI

Datavault AI™ (Nasdaq: DVLT) leads AI–driven data experiences, valuation, and monetization in the Web 3.0 environment. The Company’s cloud–based platform delivers comprehensive solutions through its collaborative Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division includes WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless HD sound. The Data Science Division harnesses Web 3.0 and high–performance computing for experiential data perception, valuation, and secure monetization across industries including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy. The Information Data Exchange® (IDE) enables Digital Twins and secure NIL licensing, fostering responsible AI with integrity. Datavault AI’s customizable technology suite offers AI/ML automation, third–party integration, analytics, marketing automation, and advertising monitoring. Headquartered in Philadelphia, PA. Learn more at www.dvlt.ai.

Forward–Looking Statements

This press release contains “forward–looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward–looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward–looking. Such forward–looking statements, including, but not limited to, statements regarding future events, whether Datavault AI will proceed with the potential dividend distribution of warrants and Datavault AI’s expectations regarding the terms and/or timing thereof (including that the Datavault Board may change the record date and/or the distribution date), the anticipated timing for announcement by Datavault AI of the record date and the distribution date, the anticipated exercise price, exercise conditions and expiration date of the warrants, the acceptance for trading of the warrants on The Nasdaq Stock Market LLC, and the existence of a market for and the future trading price of the warrants, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward–looking statements contained herein.

Actual results may differ materially from those indicated by these forward–looking statements as a result of various risks and uncertainties including, but not limited to, the following: risks related to legal proceedings that may be instituted against Datavault regarding the warrants and the dividend distribution thereof to Datavault AI’s eligible equity holders; risks associated with the right of the Datavault Board to change the record date and the distribution date, and/or to revoke the dividend prior to the distribution date; changes in economic, market, or regulatory conditions; uncertainties regarding valuation methodologies and third–party reports; risks relating to evolving regulatory frameworks applicable to tokenized assets; and other risks and uncertainties as more fully described in Datavault AI’s filings with the SEC, including its Annual Report on Form 10–K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

The forward–looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward–looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward–looking statements, and you should not place undue reliance on such forward–looking statements. Datavault AI’s forward–looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

Investor Inquiries:

[email protected]

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]


GLOBENEWSWIRE (Distribution ID 9617726)

Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI

PHILADELPHIA, Dec. 29, 2025 (GLOBE NEWSWIRE) — Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today announced two major developments to enhance and elevate the profile of Dream Bowl XIV, scheduled for Jan. 11, 2026, at AT&T Stadium, of which the Company is a licensing partner and co–sponsor.

First, Datavault AI, in collaboration with Dream Bowl XIV and NFL Alumni Health, proudly announces a strategic partnership supporting the launch of Dream Bowl Meme Coin II. This partnership underscores a shared commitment to advancing player health, wellness, and long–term care for former professional athletes, while elevating the Dream Bowl’s mission of preparing elite college football talent for the next level—both on and off the field.

“We are genuinely excited to be working with Datavault AI on a breakthrough initiative that brings artificial intelligence, digital assets, and real–world impact together for the first time,” said Billy Davis, two–time Super Bowl champion and Co–Director of Healthcare Initiatives for the NFL Alumni Association. “Datavault AI is building something truly innovative—an AI–powered token designed with purpose, transparency, and long–term potential in mind.”

Second, in commemoration of the Dream Bowl XIV and consistent with Datavault AI’s focus on applying artificial intelligence to level the playing field in professional organizations, the Company is highlighting how AI can support football organizations in identifying and evaluating talent across traditional athletics and e–sports. In connection with these initiatives, and to demonstrate how tokenization can make select aspects of the game immutable, interactive and verifiable, the Board of Directors of Datavault AI (the “Datavault Board”) has approved a dividend of the Dream Bowl Meme Coin II token to all eligible record equity holders of Datavault AI common stock and other equity securities. The record date for this dividend is Jan. 7, 2026.

The record date for the dividend may be changed by the Datavault Board for any reason at any time prior to the actual payment date, and payment of the dividend is conditioned upon the Datavault Board having not revoked the dividend prior to the payment date, including for a material change to the solvency or surplus analysis presented to the Datavault Board. Subject to the right of the Datavault Board to change the record date, the payment date for the dividend will be determined by subsequent resolutions of the Datavault Board, which payment date will be within 60 days following the record date (the “Payment Date”).

In order to receive the Dream Bowl Meme Coin II digital collectibles, all eligible recipients will be required to open a digital wallet with Datavault AI and execute an Opt–In Agreement, pursuant to which such holders will agree, among other things, to the payment conditions set forth therein, and acknowledge that such holders understand the process for receiving the Dream Bowl Meme Coin II digital collectibles, that the Datavault Board can change the record date or payment date or revoke the distribution prior to the payment date, and that the Dream Bowl Meme Coin II digital collectibles may not have or maintain any value.

The Company will provide further instructions regarding wallet setup, token access, and distribution procedures to stockholders of record of Datavault AI on the books and records of the transfer agents of Datavault AI in a subsequent communication prior to the payment date.

Datavault AI remains committed to innovative stockholder value creation. Building on the successful distribution of the original Dream Bowl Meme Coin on Dec. 24, 2025, this special Dream Bowl Meme Coin II distribution celebrates the historic NFL Alumni Health partnership and provides additional utility to stockholders. Each exclusive digital collectible will feature enhanced utility, including immutable proof of ownership. The Dream Bowl Meme Coin II will be airdropped to Data Vault® wallets on or after the Payment Date. Datavault AI will provide detailed instructions regarding wallet setup, token access, and distribution procedures in a subsequent communication prior to the Payment Date.

The Dream Bowl Meme Coin II is a digital collectible intended solely for personal, non–commercial use in connection with the Dream Bowl XIV event. The Dream Bowl Meme Coin II does not in and of itself: (i) represent or confer any equity, voting, dividend, profit–sharing, or ownership rights in Datavault AI or any other entity; (ii) provide any right to receive monetary payments, distributions, or appreciation; or (iii) create any expectation of profit or reliance on the managerial or entrepreneurial efforts of Datavault AI or others. The Dream Bowl Meme Coin II is not designed or intended to function as an investment, currency, or financial product, and it is not being offered, sold, or distributed for fundraising or capital–raising purposes. Use of the Dream Bowl Meme Coin II is limited to entertainment, event–access, and digital–collectible functions. Any transferability features are provided solely to support personal digital item portability and not to facilitate or imply investment or speculative use.

About Datavault AI

Datavault AI™ (Nasdaq: DVLT) leads AI–driven data experiences, valuation, and monetization in the Web 3.0 environment. The Company’s cloud–based platform delivers comprehensive solutions through its collaborative Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division includes WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless HD sound. The Data Science Division harnesses Web 3.0 and high–performance computing for experiential data perception, valuation, and secure monetization across industries including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy. The Information Data Exchange® (IDE) enables Digital Twins and secure NIL licensing, fostering responsible AI with integrity. Datavault AI’s customizable technology suite offers AI/ML automation, third–party integration, analytics, marketing automation, and advertising monitoring. Headquartered in Philadelphia, PA. Learn more at www.dvlt.ai.

Forward–Looking Statements

This press release contains “forward–looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward–looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward–looking. Such forward–looking statements, including, but not limited to, statements regarding future events, Datavault AI’s potential distribution of the Dream Bowl Meme Coin II and the timing thereof (including that the payment date will be determined by subsequent resolutions of the Datavault Board, and that the Datavault Board may change the record date and, as a result, the payment date, once determined), are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward–looking statements contained herein.

Actual results may differ materially from those indicated by these forward–looking statements as a result of various risks and uncertainties including, but not limited to, the following: risks related to legal proceedings that may be instituted against Datavault regarding the Dream Bowl Meme Coin II and the distribution thereof to Datavault AI’s eligible equity holders; risks associated with the right of the Datavault Board to change the record date and the payment date of the distribution of, and/or to revoke, the Dream Bowl Meme Coin II; changes in economic, market, or regulatory conditions; uncertainties regarding valuation methodologies and third–party reports; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10–K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

The forward–looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward–looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward–looking statements, and you should not place undue reliance on such forward–looking statements. Datavault AI’s forward–looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

Investor Inquiries:

[email protected]

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]


GLOBENEWSWIRE (Distribution ID 9617687)

Datavault AI Inc. Announces Issuance of Two Foundational U.S. Patents Advancing Blockchain-Driven Content Licensing and Tokenized Monetization

PHILADELPHIA, Dec. 22, 2025 (GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), a pioneer in AI–driven data valuation, monetization, and quantum–encrypted RWA tokenization, today announced the issuance of two key U.S. patents that significantly bolster its intellectual property portfolio in blockchain–based content management and monetization.

The newly issued patents cover groundbreaking systems and methods for secure content licensing and tokenized monetization using blockchain technology and smart contracts:

  • U.S. Patent (derived from Application Publication 2022/0318853): A system, method, and platform for monetizing digital content through blockchain–managed tokens. The technology automatically identifies content usage, verifies licensing via smart contracts, enforces compliance, and distributes fees according to predefined terms – enabling seamless, tamper–proof revenue sharing for creators and rights holders.
  • U.S. Patent (derived from Application Publication 2019/0155997): A comprehensive content licensing platform utilizing blockchain ledgers and secure identifiers (including patented inaudible tone integration) to register, track, license, and monetize creative works. The system supports mechanical, performance, synchronization, and micro–licensing rights while ensuring transparent royalty distribution and enforcement across global networks.

These patents directly enhance Datavault AI’s core patented technologies, including Sumerian® Crypto Anchors, DataScore, and DataValue AI agents. By combining blockchain immutability with AI–driven valuation and quantum–resistant encryption, Datavault AI is uniquely positioned to tokenize intellectual property, creative content, and data assets as secure RWAs – unlocking fractional ownership, instant settlement, and global liquidity for traditionally illiquid assets.

“The issuance of these patents represents a major milestone in our mission to empower creators and enterprises with trusted, scalable data and content monetization,” said Nathaniel T. Bradley, CEO of Datavault AI Inc. “In an era where digital content and data represent trillions in untapped value, our technologies provide the security, transparency, and automation needed to transform intellectual property into tokenized real–world assets. These patents strengthen our competitive moat and accelerate our leadership in the convergence of AI, blockchain, and RWA tokenization.”

“These patents create significant barriers to entry and robust intellectual property protections for Datavault AI, while also enabling new licensing opportunities. The continued issuance of these patents provides the foundational infrastructure for our Information Data Exchange and forthcoming Elements, NIL, and political exchanges—all built on our exclusive, quantum–secured platform,” stated Joshua Paugh, Chief Intellectual Property Officer of Datavault AI. “This includes quantum chains, quantum–grade encryption, and our unmatched command of AI combined with unprecedented blockchain technologies.”

Market Impact

The global data monetization market is projected to exceed $7 billion in 2025, growing rapidly toward $17 billion by 2033. The broader digital content and licensing industry is valued at over $369 billion globally, while real–world asset tokenization has already surpassed $30 billion in on–chain value in 2025, with analysts projecting the global tokenized real world asset market to reach over $16 trillion by 2030. Datavault AI’s expanded patent portfolio positions the company at the forefront of these converging markets, enabling secure tokenization of content rights, creative works, and proprietary data as high–value RWAs.

These advancements complement Datavault AI’s existing partnerships and initiatives in sports data monetization, global event–driven licensing, and quantum–secured blockchain infrastructure.

About Datavault AI

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud–based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry–first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi–channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high–performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud–based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real–world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third–party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.

Forward–Looking Statements

This press release contains “forward–looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward–looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward–looking. Such forward–looking statements, including, but not limited to: statements regarding future events; Datavault AI’s potential to tokenize RWAs, including metals, geothermal resources, sugar, cotton, intellectual property, creative content, and data assets; the commercial potential and anticipated market impact of our patented technologies; our ability to successfully integrate the newly issued patents referred to in this press release with our other patented technologies, including Sumerian® Crypto Anchors, DataScore, and DataValue AI agents; our ability to monitor potential infringement of and enforce our patented technologies, including the newly issued patents referred to in this press release; and the projected growth of the global data monetization and real–world asset tokenization markets, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward–looking statements contained herein.

Actual results may differ materially from those indicated by these forward–looking statements as a result of various risks and uncertainties including, but not limited to, the following: changes in economic, market, or regulatory conditions; uncertainties regarding valuation methodologies and third–party reports; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; the ability of Datavault AI to develop and successfully market technologies; the risk that the potential technologies that Datavault AI develops may not progress or receive required approvals within expected timelines or at all; risks relating to uncertainty regarding regulatory pathways; the risk that Datavault AI has overestimated the size of the target market, willingness to adopt new technologies, or partnerships; risks that prior results may not be replicated; regulatory and intellectual–property risks; and other risks and uncertainties as more fully described in Datavault AI’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10–K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

The forward–looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward–looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward–looking statements, and you should not place undue reliance on such forward–looking statements. Datavault AI’s forward–looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

Industry and Market Data

Within this press release, we reference information and statistics regarding the market for our products. We have obtained some of this information and statistics from various independent third–party sources, including independent industry publications, reports by market research firms and other independent sources. Some data and other information contained in this press release are also based on management’s estimates and calculations, which are derived from our review and interpretation of internal surveys and independent sources. Data regarding the industries in which we compete and our market position and market share within these industries are inherently imprecise and are subject to significant business, economic and competitive uncertainties beyond our control, but we believe they generally indicate size, position and market share within this industry. While we believe such information is reliable, we have not independently verified any third–party information. While we believe our internal company research and estimates are reliable, such research and estimates have not been verified by any independent source. In addition, assumptions and estimates of our and our industries’ future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially from our assumptions and estimates. As a result, you should be aware that market, ranking and other similar industry data included in this press release, and estimates and beliefs based on that data, may not be reliable.

Media Inquiries
[email protected]

Investor Contact
800.491.9665
[email protected]

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
https://www.investorbrandnetwork.com/clients/


GLOBENEWSWIRE (Distribution ID 9615834)

Nyxoah Announces Issuance of First Tranche of Convertible Bonds

Nyxoah Announces Issuance of First Tranche of Convertible Bonds

Mont–Saint–Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the issuance of the first tranche of the convertible bond financing entered into with an entity managed by Heights Capital Management (“HCM”) of up to €45 million, as previously announced by the Company on November 13, 2025.

Closing of the first tranche of the convertible bonds’ issuance

On December 18, 2025, the Company issued the first tranche of convertible bonds for a nominal amount of €22.5 million under the subscription agreement entered into with HCM on November 13, 2025, as amended and restated on December 16, 2025. The first tranche consisted of the issuance of 225 convertible bonds (the “First Tranche Bonds”) with a nominal amount of €100,000 each, which were fully subscribed to and paid–up by HCM. Pursuant to the subscription agreement, the Company has paid a subscription fee to HCM equal to 8.0 per cent of the principal amount of the First Tranche Bonds (i.e., €1.8 million), which has been satisfied by set–off against the respective portion of the subscription price of the First Tranche Bonds due by HCM.

The First Tranche Bonds carry an interest rate of 6.5 per cent per annum and have a three–year maturity from issuance with quarterly amortization payments (each a “Scheduled Amortisation Payment Date”) of principal (equal to an amount of €8.500 per First Tranche Bond, except for the final amortization payment which will be equal to €6.500 per First Tranche Bond, each an “Amortised Payment Amount”) and interest. The first Scheduled Amortisation Payment Date will be on February 18, 2026.

In addition to the scheduled amortisation payments, HCM (or any future holders of the majority of the First Tranche Bonds) may, at any time between two Scheduled Amortisation Payment Dates (a “Regular Amortisation Period”), exercise its right to bring forward the payment of up to two Amortised Payment Amounts to a date specified in a notice sent to the Company which shall not be earlier than three business days following the date on which the relevant notice is given. Additionally, HCM (or any future holders of the majority of the First Tranche Bonds) will also have the right to defer the payment of any upcoming Amortised Payment Amount to any subsequent Scheduled Amortisation Payment Date specified in the notice sent to the Company.

HCM may elect to convert the outstanding principal amount under the First Tranche Bonds or any Amortized Payment Amount at any time during the term of the bonds. The initial conversion price for the First Tranche Bonds, which can be modified on a downward basis, shall be equal to €5.00, which represents 125 per cent of the placement price of the shares that have been issued pursuant to the previously announced private placement and registered direct offering (the “Capital Increases”).

Each payment of the Amortised Payment Amounts shall in principle be done in cash at an amount equal to 103 per cent of the principal amount of such Amortised Payment Amount. However, the Company may elect to satisfy its obligation to repay the relevant Amortised Payment Amount by issuing new ordinary shares in the Company to HCM (the “Share Settlement Option”). In case the Company exercises its Share Settlement Option, the issue price for the newly to be issued ordinary shares will be the lower of (a) the conversion price in effect at the time, and (b) 90% of the lower of (i) the VWAP of an ordinary share on the relevant Scheduled Amortisation Payment Date, and (ii) the lowest of the VWAPs of an ordinary share on each of the five consecutive dealing days ending on (and including) such Scheduled Amortisation Payment Date.

More information on the First Tranche Bonds is available in the special report of the board of directors of the Company drawn up in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Code on companies and associations located at https://investors.nyxoah.com/financials.

Second tranche convertible bonds

Pursuant to the subscription agreement, the Company has the option to issue a second tranche of convertible bonds (the “Second Tranche Bonds”) to HCM for an aggregate principal amount of up to €22.5 million if so requested by the Company in the period between July 18, 2026 and August 18, 2026.

The Company and HCM can agree in writing to a lesser aggregate principal amount than €22.5 million for the Second Tranche Bonds issuance.

The obligation for HCM to subscribe to the Second Tranche Bonds on the closing date for the Second Tranche Bonds (the “Second Tranche Closing Date”) shall be subject to certain customary conditions precedent being satisfied (or waived by HCM) prior to or on the Second Tranche Closing Date. More specifically, it is, among others, required that:

  • the arithmetic mean (rounded to the nearest whole multiple of U.S.$1.00 (with U.S.$0.50 being rounded upwards)) of the daily traded values of the ordinary shares of the Company on each dealing day comprised in the period of sixty qualifying stock exchange days ending on the qualifying stock exchange date immediately preceding the date of the Company’s request to issue the Second Tranche Bonds is greater than U.S.$1 million (or its equivalent in any other currency); and
  • the Company has a last market capitalisation immediately preceding the Second Tranche Closing Date, and an average market capitalisation on each of the 30 consecutive dealing days ending on (and including) the dealing day immediately preceding the Second Tranche Closing Date that are each greater than €240,000,000.

As of December 16, 2025, the conditions precedent relating to the daily traded values, the last market capitalisation and the average market capitalisation were not met. More precisely, as of December 16, 2025, the arithmetic mean of the daily traded values amounted to U.S.$ 772,176, the last market capitalisation amounted to €177,053,883 and the 30–day average market capitalisation amounted to €175,959,735.

The Second Tranche Bonds shall, to the extent applicable, be issued on substantially the same terms as the First Tranche Bonds. The initial conversion price of the Second Tranche Bonds shall be equal to the lowest of the five VWAPs of the ordinary shares of the Company on Euronext Brussels on each of the five dealing days ending on the Second Tranche Closing Date.

Cash runway

The issuance of the First Tranche Bonds and closing of the Capital Increases, together with the second tranche under the Company’s existing credit facility with the European Investment Bank (for which the possibility to draw depends on a revenue milestone that the Company expects to meet in the first half of 2026), will extend the Company’s cash runway into the third quarter of 2026. If, in addition to the foregoing, the Second Tranche Bonds are issued, the Company’s cash runway will be extended by two (2) quarters, into the first quarter of 2027.

The net proceeds from the First Tranche Bonds together with the net proceeds of the Capital Increases will be used (i) to support commercialization activities in the United States and advance the commercialization of the Genio system in the Company’s initial target markets outside the United States; (ii) to continue gathering clinical data and to support physician–initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to Genio system upgrades, re–designing the Company’s products for manufacturability and cost reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

IMPORTANT INFORMATION

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE, OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE, ANY SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER, SUBSCRIPTION, SALE AND PURCHASE OF SECURITIES DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the convertible bond financing; the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the satisfaction of the closing conditions required for the Second Tranche Bonds and the corresponding closing, the use of net proceeds from the First Tranche Bonds, the expected sufficiency of the Company’s cash resources and runway, which may not be accurate resulting in the need for additional financing sooner than anticipated, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the SEC on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001145999)

Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles

Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles

Mont–Saint–Guibert, Belgique – 19 décembre 2025, 10:05p.m. CET / 4:05p.m. ET – Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (AOS) par neuromodulation, a annoncé aujourd'hui l’émission de la première tranche du financement par obligations convertibles conclu avec une entité gérée par Heights Capital Management (« HCM ») jusqu’à €45 millions, comme annoncé précédemment par la Société le 13 novembre 2025.

Clôture de la première tranche de l’émission des obligations convertibles

Le 18 décembre 2025, la Société a émis la première tranche des obligations convertibles pour un montant nominale de €22.5 millions sous le contrat de souscription conclu avec HCM le 13 novembre 2025, tel que modifié le 16 décembre 2025. La première tranche consiste en l’émission de 225 obligations convertibles (les « Obligations de la Première Tranche ») avec une valeur nominale de €100,000 chacune, qui ont été entièrement souscrites et libérées par HCM. Conformément au contrat de souscription, la Société a payé des frais de souscription à HCM pour un montant total égal à 8% du montant initial des Obligations de la Première Tranche (i.e., €1.8 million), qui ont fait l’objet d’une compensation avec la partie correspondante du prix de souscription des Obligations de la Première Tranche dues par HCM.

Les Obligations de la Première Tranche portent intérêt au taux annuel de 6,5 % et ont une échéance de trois ans à compter de leur émission avec des remboursements trimestriels (chacune étant une « Date de Paiement d’Amortissement Prévue ») du montant initial (égal à un montant de €8.500 par Obligation de la Première Tranche, à l’exception du remboursement final qui sera égal à €6.500 par Obligation de la Première Tranche, chacun étant un « Montant de Paiement Amorti ») et de l’intérêt. La première Date de Paiement d’Amortissement Prévue sera le 18 février 2026.

Outre les remboursements prévus, HCM (ou tout futur détenteur de la majorité des Obligations de la Première Tranche) peut, à tout moment entre deux Dates de Paiement d'Amortissement Prévues (une « Période d'Amortissement Régulière »), exercer son droit d'avancer le paiement d'un maximum de deux Montants de Paiement Amortis à une date précisée dans un avis envoyé à la Société, qui ne peut être antérieure au troisième jour ouvrable suivant la date à laquelle l'avis pertinent est donné. En outre, HCM (ou tout futur détenteur de la majorité des Obligations de la Première Tranche) aura également le droit de reporter le paiement de tout Montant de Paiement Amorti à venir à toute Date de Paiement d'Amortissement Prévue ultérieure spécifiée dans l'avis envoyé à la Société.

HCM peut choisir de convertir le montant principal impayé des Obligations de Première Tranche ou chaque Montant de Paiement Amorti à tout moment pendant la durée des obligations. Le prix de conversion par défaut pour les Obligations de la Première Tranche, qui peut être modifié à la baisse, sera égal à €5.00, ce qui représente 125 % du prix de placement des actions émises dans le cadre du placement privé et de l’offre directe enregistrée annoncés précédemment (les « Augmentations de Capital »).

Chaque paiement des Montants de Paiement Amortis doit en principe être effectué en espèces pour un montant égal à 103 pour cent du montant initial d’un tel Montant de Paiement Amorti. Cependant, la Société peut choisir de satisfaire son obligation de payer le Montant de Paiement Amorti pertinent par l’émission de nouvelles actions ordinaires de la Société à HCM (l’ « Option de Règlement en Actions »). Au cas où la Société exerce son Option de Règlement en Actions, le prix d’émission des actions nouvelles ordinaires à émettre sera le plus bas des deux montants suivants: (a) le prix de conversion alors en vigueur et (b) 90 % du (i) prix moyen pondéré en fonction du volume d’une action ordinaire à la Date du Paiement d’Amortissement Prévue pertinente, et (ii) le plus bas des cinq prix moyens pondérés en fonction du volume d’une action ordinaire sur chacun des cinq jours de négociation consécutifs se terminant à (et incluant) cette Date du Paiement d’Amortissement Prévue.

De plus amples informations sur les Obligations de la Première Tranche sont disponibles dans le rapport spécial du conseil d'administration de la Société établi conformément aux articles 7:180, 7:191 et 7:193 du Code des sociétés et associations, disponible à l'adresse https://investors.nyxoah.com/financials.

Deuxième tranche des obligations convertibles

Conformément au contrat de souscription, la Société a l’option d’émettre une deuxième tranche des obligations convertibles (les « Obligations de la Deuxième Tranche ») à HCM pour un montant total maximal de €22.5 millions si demandé par la Société pendant la période entre le 18 juillet 2026 et le 18 août 2026.

La Société et HCM peuvent convenir par écrit d’un montant total inférieur à €22.5 millions pour les Obligations de la Deuxième Tranche.

L’obligation de HCM de souscrire aux Obligations de la Deuxième Tranche à la date de clôture des Obligations de la Deuxième Tranche (la « Date de Clôture de la Deuxième Tranche ») est soumise à certaines conditions préalables habituelles étant satisfaites (ou renoncé par HCM) avant ou à la Date de Clôture de la Deuxième Tranche. Plus précisément, il faut que, en outre:

        1. la moyenne arithmétique (arrondie au multiple entier le plus proche de U.S.$1.00 (U.S.$0.50 étant arrondi à la hausse)) des valeurs quotidiennes négociées des actions ordinaires de la Société pour chaque jour de bourse admissible compris dans la période de 60 jours de bourse admissibles consécutifs se terminant le jour de bourse admissible précédant immédiatement la date de l’avis de la Société d’émettre les Obligations de la Deuxième Tranche soit supérieure à U.S.$1 million (ou son équivalent dans toute autre devise); et
        1. la Société ait une dernière capitalisation boursière immédiatement avant la Date de Clôture de la Deuxième Tranche, et une capitalisation boursière moyenne sur chacun des 30 jours de négociation consécutifs terminant le jour de négociation immédiatement avant la Date de Clôture de la Deuxième Tranche (inclus), qui sont chacune supérieure à 240.000.000 €.

Au 16 décembre 2025, les conditions préalables relatives aux valeurs quotidiennes négociées, à la dernière capitalisation boursière et à la capitalisation boursière moyenne n’étaient pas remplies. Plus précisément, au 16 décembre 2025, la moyenne arithmétique des valeurs quotidiennes négociées s’élevait à U.S.$ 772,176, la dernière capitalisation boursière s’élevait à €177,053,883, et la capitalisation boursière moyenne sur 30 jours s’élevait à €175,959,735.

Les Obligations de la Deuxième Tranche seront, dans la mesure applicable, émis à des conditions substantiellement identiques que les Obligations de la Première Tranche. Le prix de conversion par défaut des Obligations de la Deuxième Tranche sera égal au plus bas des cinq prix moyens pondérés en fonction du volume des actions ordinaires de la Société sur Euronext Bruxelles à chacune des cinq jours de négociation se terminant à la Date de Clôture de la Deuxième Tranche.

Trésorerie

L’émission d’Obligations de la Première Tranche et la clôture des Augmentations de Capital ainsi que la deuxième tranche au titre de la facilité de crédit existante de la Société auprès de la Banque européenne d’investissement (dont la possibilité de tirage dépend d’un objectif de chiffre d’affaires que la Société prévoit d’atteindre au cours du premier semestre 2026), prolongeront la trésorerie de la Société jusqu’au troisième trimestre 2026. Si, en plus de ce qui précède, la Deuxième Tranche d’Obligations est émise, cela prolongerait la trésorerie disponible de la Société de deux trimestres, jusqu’au premier trimestre 2027.

Le produit net des Obligations de la Première Tranche ensemble avec le produit net des Augmentations de Capital, seront utilisés pour (i) lancer des activités de commercialisation aux États–Unis et faire progresser la commercialisation du système Genio sur ses marchés cibles initiaux en dehors des États–Unis; (ii) poursuivre la collecte de données cliniques et  soutenir les projets de recherche clinique initiés par des médecins et liés aux traitements des patients atteints d’AOS; (iii) financer davantage les activités de recherche et développement liées aux mises à niveau du système Genio, à la refonte de nos produits pour en améliorer la fabricabilité et à des initiatives de réduction des coûts; (iv) continuer à développer un pipeline de nouvelles technologies et à explorer les possibilités de collaboration dans le domaine de la surveillance et du diagnostic de l’AOS; et (v) à d’autres fins générales de l’entreprise, y compris, sans s’y limiter, le fonds de roulement, les dépenses en capital, les investissements, les acquisitions, si la Société décide de les poursuivre, et les collaborations.

Le présent communiqué de presse ne constitue pas une offre de vente ou la sollicitation d'une offre d'achat des titres, et il n'y aura pas de vente des titres dans un État où une telle offre, sollicitation ou vente serait illégale avant l'enregistrement ou la qualification en vertu des lois sur les valeurs mobilières de cet État.

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

INFORMATIONS IMPORTANTES

LE PRÉSENT COMMUNIQUÉ NE DOIT PAS ÊTRE DISTRIBUÉ, DIRECTEMENT OU INDIRECTEMENT, DANS UNE JURIDICTION OÙ CELA SERAIT INTERDIT PAR LA LOI. CE COMMUNIQUE EST UNIQUEMENT DESTINE A L'INFORMATION GENERALE ET NE FAIT PAS PARTIE D'UNE OFFRE DE VENTE OU D'ACHAT, OU DE LA SOLLICITATION D'UNE OFFRE DE VENTE OU D'ACHAT, DE VALEURS MOBILIERES. LA DISTRIBUTION DE CE COMMUNIQUE ET L'OFFRE, LA SOUSCRIPTION, LA VENTE ET L'ACHAT DES TITRES DECRITS DANS CE COMMUNIQUE DANS CERTAINES JURIDICTIONS PEUVENT ETRE RESTREINTES PAR LA LOI. TOUTE PERSONNE LISANT CETTE ANNONCE DOIT S'INFORMER DE CES RESTRICTIONS ET LES RESPECTER.

DÉCLARATIONS PROSPECTIVES

Certaines déclarations, convictions et opinions contenues dans le présent communiqué de presse sont prospectives et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le financement par obligations convertibles, le système Genio®; les études cliniques prévues et en cours sur le système Genio®; les avantages potentiels du système Genio®; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio® ; la stratégie de commercialisation de la Société et son entrée sur le marché américain; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la Société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, de manière non–exhaustive, la satisfaction des conditions requises pour la clôture des Obligations de la Deuxième Tranche, ainsi que la réalisation de la clôture respective, l’utilisation du produit net des Obligations de la Première Tranche, la suffisance attendue des ressources de trésorerie et la durée du financement de la Société, qui pourrait s'avérer inexacte et entraîner la nécessité d'un financement supplémentaire plus tôt que prévu, les risques et incertitudes énoncés dans la section « Risk Factors » du Annual Report on Form 20–F de la Société pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou les activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001145999)

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
First Genio implants successfully performed at OLVG West and Zuyderland hospitals

Mont–Saint–Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio® system in the Netherlands, marked by the first successful Genio implants performed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen.

Commenting on the introduction of Genio in Amsterdam, Dr. Peter van Maanen, ENT surgeon at OLVG West, stated: “Dr. Mayke Hentschel, our sleep department and I are pleased to offer our patients an additional treatment option for OSA when CPAP is not tolerated. With Genio, patients finally have a real choice. The system stimulates both branches of the nerve, has no internal battery, is full body 1.5 and 3T MRI–compatible, and can be easily upgraded via the external activation chip. These features make it a promising long–term solution for both patients and healthcare providers.”

At Zuyderland Hospital, Dr. Jos Straetmans, ENT surgeon in Heerlen and Sittard, added: “Introducing the Genio bilateral neurostimulation system expands our ability to tailor therapy to the needs of each individual patient. Its advantages: no implanted battery, and reliable performance in the supine position make it a valuable addition to our treatment arsenal. We are excited to bring this innovative, European developed technology to patients in our community.”

“The commercial launch of Genio in the Netherlands marks another important step in our European rollout and reflects growing adoption of our bilateral, externally powered Genio therapy,” commented Olivier Taelman, Nyxoah's Chief Executive Officer. “We are proud to partner with leading Dutch centers to bring Genio to patients seeking an effective and patient–centric alternative to CPAP. As we continue to expand our commercial footprint, these early implants further validate Genio’s role as a long–term solution for OSA.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centric, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001145284)